Gain Therapeutics Company Profile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gain Therapeutics (NASDAQ:GANX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. GANX has been the topic of a number of other reports. Chardan Capital reissued a buy rating and set a […]

Jeffrey scott rileySecurities exchange commissionGain therapeutics incGain therapeutics company profileGain therapeuticsFree reportGet free reportDirector jeffrey scott rileyExchange commissionGain therapeutics daily

Gain Therapeutics, Inc (NASDAQ:GANX) Sees Significant Growth in Short Interest

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 149,600 shares, a growth of 8.3% from the March 31st total of 138,100 shares. Currently, 1.1% of the company’s shares are short sold. Based on an […]

Jeffrey scott rileyGain therapeutics company profileGain therapeutics incGain therapeuticsGet free reportDirector jeffrey scott rileyGain therapeutics dailyNasdaq ganx

Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Jeffrey scott rileyGain therapeutics incGain therapeutics company profileGain therapeuticsFree reportGet free reportDirector jeffrey scott rileyGain therapeutics daily

Gain Therapeutics, Inc (NASDAQ:GANX) Director Jeffrey Scott Riley Acquires 30,000 Shares

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average cost of $3.86 per share, for a total transaction of $115,800.00. Following the purchase, the director now directly owns 30,000 shares in […]

Jeffrey scott rileyNewedge advisorsRenaissance technologiesSecurities exchange commissionSusquehanna international groupDimensional fund advisorsGain therapeutics company profileGain therapeutics incGain therapeuticsGet free reportDirector jeffrey scott rileyExchange commissionFund advisorsStreet groupEdge advisorsInternational group

Gain Therapeutics, Inc Expected to Post Q1 2024 Earnings of ($0 46) Per Share (NASDAQ:GANX)

Gain Therapeutics, Inc Expected to Post Q1 2024 Earnings of ($0 46) Per Share (NASDAQ:GANX)
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

United kingdom generalUnited kingdomGain therapeutics incDimensional fund advisorsGain therapeutics company profileNewedge advisorsSusquehanna international groupBlackrock incGain therapeuticsFree reportGain therapeuticChardan capitalEdge advisorsStreet groupFund advisorsInternational group